Leuprolide: structure, approvals, trials and status

Leuprolide is a synthetic GnRH agonist peptide; this guide covers its FDA approvals, the trials behind them and its label warnings, as of November 17, 2026.

Complete guide6 min read

Key takeaway

Leuprolide is a synthetic nine-unit peptide and a GnRH agonist. FDA first approved it in 1985 as Lupron. Its labels cover advanced prostate cancer, endometriosis, anemia from uterine fibroids before surgery, and central precocious puberty. In a 1984 prostate cancer trial, objective response was 86% with leuprolide and 85% with an estrogen drug.

At a glance

Article typeComplete guide
Regulatory statusFDA-approved“FDA first approved leuprolide on April 9, 1985, as Lupron.” (this article)
ClassReproductive hormones
Body systemsReproductive system
Studies cited4 in this article · 4 across 1 article on Leuprolide
Related productsResearch peptide catalog

Leuprolide is a lab-made version of gonadotropin-releasing hormone (GnRH), the brain signal that starts sex hormone production. This guide covers its structure, how it works, what FDA approved it for, the key trials and what its labels warn about. Sources were checked on November 17, 2026.

Quick answer: Leuprolide is a prescription peptide drug that copies GnRH. It first raises, then suppresses, the pituitary hormones that drive the testes and ovaries. That lowers testosterone and estrogen.

Vitrapep does not sell leuprolide; this page is a reference summary of published research and regulatory information. It is not medical advice.

What is leuprolide?

Leuprolide is a synthetic peptide. The Lupron Depot label calls it “a synthetic nonapeptide analog of naturally occurring gonadotropin-releasing hormone (GnRH)” (Lupron Depot label). Nonapeptide means a chain of nine amino acids.

Its chemical name lists pyroglutamic acid, histidine, tryptophan, serine, tyrosine, leucine, leucine, arginine and proline. The leucine at position 6 is a D-amino acid, the mirror-image form. The chain ends in an N-ethyl prolinamide group.

PubChem lists the formula of leuprolide as C59H84N16O12 and its molecular weight as 1209.4 g/mol (PubChem CID 657181). FDA first approved leuprolide on April 9, 1985, as Lupron. Drugs@FDA lists it under NDA 019010 (Drugs@FDA). For background, see our overview of peptide hormones.

Table 1

Leuprolide: key facts

Fact Detail
Structure Synthetic peptide of nine units with a D-leucine at position 6 and an N-ethyl prolinamide end
Class GnRH agonist
Molecular formula C59H84N16O12 (PubChem)
Molecular weight 1209.4 g/mol (PubChem)
First FDA approval April 9, 1985 (Lupron, NDA 019010)
Approved brands Lupron Depot, Lupron Depot-PED, Eligard, Fensolvi and others

How does leuprolide work?

Natural GnRH travels from the brain to the pituitary gland. There it triggers the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). These drive the testes and ovaries to make sex hormones. Our gonadorelin guide covers natural GnRH.

Leuprolide binds the same pituitary receptors. At first it acts like GnRH, so LH, FSH and sex hormone levels rise. The Lupron Depot label says leuprolide “acts as an inhibitor of gonadotropin secretion” once exposure is sustained. It cites animal studies showing initial stimulation, then reversible suppression of ovarian and testicular steroid production.

In human trials, leuprolide suppressed testosterone in men and lowered estradiol to menopausal levels in women (1984; 1990). The early rise is why prostate cancer labels carry a “Tumor Flare” warning.

What is leuprolide approved for?

Approved uses are set product by product, following section 1 of each label.

  • Lupron Depot (adult prostate products): “the treatment of advanced prostate cancer.” Eligard carries the same indication (Eligard label).
  • Lupron Depot (gynecology products): management of endometriosis, including pain relief and reduction of endometriotic lesions. It is also labeled with norethindrone acetate for painful symptoms of endometriosis. With iron therapy, it is labeled for preoperative improvement of anemia caused by uterine fibroids (Lupron Depot gynecology label).
  • Lupron Depot-PED: “the treatment of pediatric patients with central precocious puberty (CPP)” (Lupron Depot-PED label).
  • Fensolvi: “the treatment of pediatric patients 2 years of age and older with central precocious puberty” (Fensolvi label).

Central precocious puberty is puberty that starts early because the brain’s GnRH signal switches on early. See also our guides to triptorelin and goserelin.

What did the key trials of leuprolide show?

All three trials below enrolled people.

Prostate cancer, 1984. The Leuprolide Study Group randomized 199 men with metastatic prostate cancer and no prior systemic treatment. Ninety-eight received leuprolide and 101 received diethylstilbestrol (DES), an estrogen drug. Objective response was 86% with leuprolide and 85% with DES. One-year survival was 87% versus 78%, a difference that was not significant (P = 0.17). DES caused more painful breast enlargement, nausea and vomiting, and edema. Leuprolide caused more hot flashes (N Engl J Med, 1984).

Endometriosis, 1990. A double-blind, placebo-controlled trial randomized 52 women with endometriosis. Painful periods, pelvic pain and pelvic tenderness improved significantly more with leuprolide than with placebo. Vasodilatation was the most common adverse event and was significantly more frequent with leuprolide (Fertil Steril, 1990).

Central precocious puberty, 2020. A Phase 3, open-label, single-arm trial tested Fensolvi in 64 children (NCT02452931). The primary endpoint was LH suppression at week 24. In all, 54 of 62 children (87%) had stimulated LH below 4 IU/L. Adverse events were mild, and none led to stopping treatment (Klein et al., 2020). There was no comparison group.

What side effects does the leuprolide label list?

None of the leuprolide labels we read carries a boxed warning. The most common adverse reactions differ by product:

  • Lupron Depot, prostate: reactions vary by version. For one, those above 10% were general pain, hot flashes or sweats, GI disorders, edema, respiratory disorder and urinary disorder.
  • Eligard: malaise, fatigue, hot flashes or sweats, and testicular atrophy, each at 5% or more.
  • Lupron Depot, gynecology: above 10%, hot flashes or sweats, headache or migraine, vaginitis, depression, general pain, weight change, nausea, decreased libido and dizziness.
  • Fensolvi: at 5% or more, injection site pain, nasopharyngitis and pyrexia, among others.

Prostate label warnings include tumor flare, hyperglycemia and diabetes, cardiovascular disease, QT prolongation and convulsions. The gynecology label adds bone mineral density loss and depression. Pediatric labels add psychiatric events and pseudotumor cerebri, raised pressure around the brain.

What is the regulatory status of leuprolide, and is it used in research?

Leuprolide is a prescription drug; its labels are marked “Rx only.” On October 20, 2010, FDA notified makers of GnRH agonists of new safety information for labeling. It covered diabetes and certain cardiovascular diseases: heart attack, sudden cardiac death and stroke. The agreed text says the risk “appears low based on the reported odds ratios” (FDA, 2011).

On July 1, 2022, FDA added a pseudotumor cerebri warning to GnRH agonists for central precocious puberty, including Lupron Depot-Ped and Fensolvi. FDA found six cases supporting a plausible link, all in birth-assigned females aged 5 to 12 (FDA, 2022).

In sport, WADA’s 2026 Prohibited List names leuprorelin under S2.2.1, “Testosterone-stimulating peptides in males.” S2 substances are prohibited at all times, in and out of competition. Athletes should check with their anti-doping organization. See our guide to the 2026 WADA list.

Researchers also use leuprolide in animals to lower reproductive hormones. In one study, leuprolide suppressed LH in aged Alzheimer model mice. Compared with placebo, they showed less cognitive decline and amyloid-beta buildup (Casadesus et al., 2006). These are mouse data and do not show an effect in people. See also what research use only means.

Frequently asked questions about leuprolide

Is leuprolide the same as Lupron?

Leuprolide is the active ingredient. Lupron was its first FDA-approved brand, in 1985. Lupron Depot, Eligard and Fensolvi are other leuprolide products.

Is leuprolide the same as leuprorelin?

Yes. PubChem lists leuprorelin as a synonym for leuprolide, and the WADA list uses the name leuprorelin.

Why does leuprolide raise hormone levels before lowering them?

It first acts like natural GnRH and stimulates the pituitary. With sustained exposure, LH and FSH secretion is suppressed. Labels warn about this early rise.

Is leuprolide banned in sport?

WADA’s 2026 list names leuprorelin under S2.2.1, testosterone-stimulating peptides in males. S2 substances are prohibited at all times.

Does leuprolide have a boxed warning?

None of the labels we read has one. Warnings include tumor flare, metabolic and cardiovascular risks, and pseudotumor cerebri in children.

What to know now

  • What it is: a synthetic nine-unit GnRH agonist peptide.
  • Approval: first FDA approval April 9, 1985, as Lupron.
  • Labeled uses: advanced prostate cancer, endometriosis, anemia from fibroids before surgery, and central precocious puberty.
  • Safety: no boxed warning; FDA class actions in 2010 and 2022.
  • Sport: WADA prohibits leuprorelin in males at all times.

What we’re watching

New leuprolide labels and FDA safety updates. WADA’s 2027 Prohibited List, which takes effect on January 1, 2027. Our guides to degarelix and gonadorelin cover other ways to act on the same hormone axis.

More for reproductive system

All 12 compounds for reproductive system

Sources: AbbVie Inc 2026, LUPRON DEPOT (leuprolide acetate) prescribing information, advanced prostate cancer; AbbVie Inc 2025; AbbVie Inc 2025, LUPRON DEPOT-PED (leuprolide acetate) prescribing information; Tolmar Inc 2026, ELIGARD (leuprolide acetate) prescribing information; Tolmar Inc 2025, FENSOLVI (leuprolide acetate) prescribing information; U.S. Food and Drug Administration. Drugs@FDA: Lupron (leuprolide acetate), Drugs@FDA: Lupron (leuprolide acetate), NDA 019010; National Center for Biotechnology Information. PubChem compound summary for CID 657181, PubChem compound summary for CID 657181, leuprolide; Leuprolide Study Group 1984, New England Journal of Medicine, 311; Dlugi 1990, Fertility and Sterility, 54; Klein 2020, Journal of Clinical Endocrinology & Metabolism, 105; U.S. Food and Drug Administration 2011; U.S. Food and Drug Administration 2022, Risk of pseudotumor cerebri added to labeling for gonadotropin-releasing hormone agonists; World Anti-Doping Agency 2025, World Anti-Doping Code International Standard: Prohibited List 2026; Casadesus 2006, Biochimica et Biophysica Acta, 1762. All 14 citations

Back to the research library

References

  1. AbbVie Inc. (2026). LUPRON DEPOT (leuprolide acetate) prescribing information, advanced prostate cancer (revised March 2026). DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cbc8f94e-7330-4465-05ad-16d64493a5dd
  2. AbbVie Inc. (2025). LUPRON DEPOT (leuprolide acetate) prescribing information, endometriosis and uterine fibroids (revised September 2025). DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00c486b0-bd7b-4898-834d-8c656e5e73cb
  3. AbbVie Inc. (2025). LUPRON DEPOT-PED (leuprolide acetate) prescribing information (revised November 2025). DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e99f47d2-da10-3127-ecb3-e5d942ae6e81
  4. Tolmar Inc. (2026). ELIGARD (leuprolide acetate) prescribing information (revised April 2026). DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b7b679a9-6823-4ef8-8d31-3ab5058ffcfc
  5. Tolmar Inc. (2025). FENSOLVI (leuprolide acetate) prescribing information (revised September 2025). DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c311700-edf4-4f2a-a468-9875489a6cc7
  6. U.S. Food and Drug Administration. Drugs@FDA: Lupron (leuprolide acetate), NDA 019010. Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019010
  7. National Center for Biotechnology Information. PubChem compound summary for CID 657181, leuprolide. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/657181
  8. Leuprolide Study Group. (1984). Leuprolide versus diethylstilbestrol for metastatic prostate cancer. New England Journal of Medicine, 311(20), 1281–1286. https://doi.org/10.1056/NEJM198411153112004
  9. Dlugi, A. M., Miller, J. D., & Knittle, J. (1990). Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: A randomized, placebo-controlled, double-blind study. Fertility and Sterility, 54(3), 419–427. https://doi.org/10.1016/s0015-0282(16)53755-8
  10. Klein, K. O., Freire, A., Gryngarten, M. G., Kletter, G. B., Benson, M., Miller, B. S., Dajani, T. S., Eugster, E. A., & Mauras, N. (2020). Phase 3 trial of a small-volume subcutaneous 6-month duration leuprolide acetate treatment for central precocious puberty. Journal of Clinical Endocrinology & Metabolism, 105(10), e3660–e3671. https://doi.org/10.1210/clinem/dgaa479 (ClinicalTrials.gov ID NCT02452931)
  11. U.S. Food and Drug Administration. (2011, January 14). Supplement approval letter, NDA 021088/S-025 (leuprolide acetate), citing FDA’s October 20, 2010 GnRH agonist safety notification. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/021088s025ltr.pdf
  12. U.S. Food and Drug Administration. (2022, July 1). Risk of pseudotumor cerebri added to labeling for gonadotropin-releasing hormone agonists. https://www.fda.gov/media/159663/download
  13. World Anti-Doping Agency. (2025). World Anti-Doping Code International Standard: Prohibited List 2026 (in effect January 1, 2026). https://www.wada-ama.org/en/prohibited-list
  14. Casadesus, G., Webber, K. M., Atwood, C. S., Pappolla, M. A., Perry, G., Bowen, R. L., & Smith, M. A. (2006). Luteinizing hormone modulates cognition and amyloid-beta deposition in Alzheimer APP transgenic mice. Biochimica et Biophysica Acta, 1762(4), 447–452. https://doi.org/10.1016/j.bbadis.2006.01.008